What Researchers Did
Tunisian researchers reviewed records of 46 patients who received HBOT for osteoradionecrosis (jaw and skull bone death after radiation therapy for head and neck cancer) to identify which factors predicted whether their condition improved or got worse.
What They Found
After an average of 44.65 HBOT sessions, ORN regressed in 33% of patients, stabilized in 45%, and worsened in 22%. More HBOT sessions correlated with better outcomes (p = 0.001). High blood pressure, larger tumor size, higher radiation dose, and the interval between dental care and radiation also significantly influenced outcomes.
What This Means for Canadian Patients
Osteoradionecrosis is a painful, disfiguring complication that can affect Canadians who received head and neck radiation therapy years or even decades earlier. This study confirms that completing a full course of HBOT (not stopping early) improves outcomes, and that patients with high blood pressure or prior high-dose radiation need extra monitoring during treatment.
Canadian Relevance
Osteoradionecrosis is an OHIP-covered indication for HBOT in Ontario. Canadians who have received radiation to the head and neck and develop jaw bone problems may qualify for publicly funded HBOT.
Study Limitations
This retrospective study from a single center included only 46 patients, and multivariate analysis reduced statistical power, so the identified risk factors may not apply universally.